SK bioscience

Self-developed cell-culture influenza vaccine available in quadrivalent and trivalent forms, included among the company's WHO PQ-certified products.

Self-developed varicella vaccine SKYVaricella and herpes zoster vaccine SKYZoster; SKYVaricella is WHO PQ-certified.

Vaccine manufacturing site in Pungsan-eup, Andong, North Gyeongsang. In July 2026 it passed the triennial WHO GMP review of four WHO PQ vaccines by document assessment, and its commercial production capacity has been expanded for global supply of GBP410, the pneumococcal vaccine in development with Sanofi.

German subsidiary whose performance improved in 2026 on higher production volumes for key customers and yield improvements.

Signed a vaccine technology-transfer agreement with Colombian state-owned pharmaceutical company VECOL, starting with the SKYVaricella varicella vaccine and covering facility construction, product introduction, regulatory approval and production know-how.

Signed a license agreement with the U.S. CDC for an injectable inactivated rotavirus vaccine technology, taking on process development, clinical trials, approval and commercialization.

Passed the periodic WHO GMP review of four WHO PQ vaccines made at Andong L HOUSE (SKYCellflu, SKYCellflu Quadrivalent, SKYVaricella, SKYTyphoid) by document assessment without an on-site inspection.

Filed a clinical trial application with South Africa's SAHPRA for a global Phase 1b study of RSM01, an RSV preventive antibody licensed from Gates MRI in February 2026.